Hi Folks,
I have had a reply from Dr Paul Goldberg at Xenon concerning a question I asked about clinical trials, he sent me a very comprehensive reply around care and management for our Daughter. I thought this was extremely decent of him , here is the paragraph concerning trials etc. Apologies if this is information you may already have.
Dear David
I am sorry to hear about the terribly difficult situation with your daughter. I have had a lot of interactions with patients with erythromelalgia over the past several years and have learnt a lot about this condition. I am keen to help you where possible. Unfortunately, the drug is still an experimental drug and thus we are legally unable to provide it to Emily at this time. It is not yet approved and can only be used under very strict regulatory conditions in a clinical trial setting. The next clinical trial is at least a year away and so this option will not be of help in the near term. Furthermore, unfortunately, the drug has not yet been tested in the paediatric setting and thus Emily at this time would not be eligible for the upcoming trial.
I do want to leave you with a positive note. I know the situation looks bleak at the moment and that Emily is suffering badly. However, with persistence and repeated evaluation of the wide variety of existing medications, many patients do find some measure of relief and some achieve dramatic improvements. Furthermore, the drug we are developing is targeted at the root cause of the disease (ie a defective sodium channel) and we are very encouraged that this mode of intervention will prove highly beneficial for patients with erythromelalgia.
With kind regards
Paul Goldberg
So the next clinical trial is a year away and this was the address I sent the query to research@xenon-pharma.com. It may be worthwhile contacting Xenon to see if you are eligible for the trial. For the moment Emily has a heart ultrasound in the morning, all going well she will be having a Licocaine infusion followed up by oral mexilitine hopefully within the next few weeks.